Effect of Intranasal Vasopressin on Cooperative Behavior in Schizophrenia

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04190004

Enrollment

Registered

2019-12-09

Start date

2018-01-01

Completion date

2018-11-30

Last updated

2019-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Brief summary

The study investigates the effect of 40IU of intranasal vasopressin on cooperative behavior in patients with schizophrenia

Interventions

DRUGVasopressins

40 International units of vasopressin or placebo will be given intra-nasally. The order of the administration will be counterbalanced

DRUGPlacebo

40 International units of vasopressin or placebo will be given intra-nasally. The order of the administration will be counterbalanced

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

OTHER

Masking

DOUBLE (Subject, Investigator)

Masking description

Double

Intervention model description

After completion of clinical assessments all subjects will receive either 40 IU of vasopressin or saline in counterbalanced order on two separate days and perform the behavioral tasks

Eligibility

Sex/Gender

ALL

Age

18 Years to 45 Years

Healthy volunteers

Inclusion criteria

* Age 18-45 years * Diagnosed as Schizophrenia or Schizophreniform disorder as per DSM IV TR * At least 7 years of formal education * MOCA score \>24

Exclusion criteria

* Diagnoses of SIADH, Diabetes Insipidus * Substance dependence in the past 12 months, excluding nicotine dependence * Current comorbid axis 1 psychiatric disorder * Hypersensitivity or previous allergy to Vasopressin * Serious medical or neurological illness which may interfere with assessment and administration of vasopressin * Hypertension * Impaired renal functions based on serum creatinine above 1.5 * Electrolyte imbalance * Receiving ECT or has received ECT in the past 8 weeks * Clinical history of mental retardation * Pregnancy • Lactation * Risk of harm to self or others * Any significant nasal pathology which may hinder the intranasal absorption of the drug * Hearing or visual impairment that significantly affects the comprehension and execution of the study

Design outcomes

Primary

Measure	Time frame	Description
Performance in Dictator game	60 minutes	Amount of money shared in dictator game
Performance in stag hunt game	60 minutes	Security level in stag hunt game

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026